Will other vaccines provide long-term protection against this variant?
The AstraZeneca vaccine offers essentially zero protection against the South African variant of SARS-CoV-2, dubbed B.1.351. In contrast, the JNJ vaccine and Novavax vaccine offer some protection against B.1.351.
inDemic Foundation and our director, Dr. Sam Sun, have recently been featured by several news sources to discuss topics on vaccine confidence and vaccine hesitancy.
Watch these discussions on:
Join inDemic Foundation Director Dr. Sam Sun and Professor Bernice Hausman of Penn State University’s College of Medicine for a discussion about vaccine hesitancy. A substantial portion of the population may be hesitant about receiving the COVID-19 vaccine. Dr. Sun and Dr. Hausman will offer insight into the rational, emotional and social factors that may be influencing the decision-making process—and what will happen if too many people refuse the vaccine.
In this video interview, we discuss vaccine hesitancy, first in measles as a historical backdrop, then for a potential or soon-to-be FDA authorized COVID-19 vaccine. Dr. Abram Wagner, research assistant professor of epidemiology at the University of Michigan, joins us to discuss recent research on vaccine hesitancy. His research looks at evidence-based programs and policies to control vaccine-preventable diseases. He currently holds a grant from the National Science Foundation that looks at behaviors and acceptance of a COVID-19 vaccine over time and across several regions, including the United States, India, and Taiwan.
Last week, the UK’s regulatory agency approved Pfizer/BioNTech’s COVID-19 vaccine (BNT162b2) for emergency use. Quietly, the UK’s Joint Committee on Vaccination and Immunization (JCVI) also published priorities for populations to be vaccinated.
Like the United States, the UK is in a unique position. It will be among the first countries to roll out the highly effective Pfizer/BioNTech vaccine. However, it will be unable to vaccinate its entire populace with the first, or even the entirety of its Pfizer/BioNTech supply agreement in 2020-2021. Eventually however, many months from now, with a combination of Pfizer/BioNTech, Moderna, and possibly other vaccines currently undergoing phase 3 trials, the USA and the UK will be able to vaccinate its entire population.
Over the past week, inDemic Foundation’s Director, Dr. Sam Sun, was featured on several news channels to discuss and compare the Pfizer and Moderna vaccines.
Watch his discussions on:
In this video interview, we discuss the strengths and limitations of COVID-19 vaccine candidates with Dr. Deborah Fuller, Professor of Microbiology at University of Washington. Her lab, which studies influenza, HIV, and Zika virus, is currently focused on immunity against COVID-19 and the development of novel vaccination strategies against SARS-CoV-2. Her lab’s work has resulted in over a dozen patents and two startup biotech companies.